---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-005555"
form_type: "8-K"
ticker: "FEED"
cik: "0001326706"
company_name: "ENvue Medical, Inc."
filed_at: "2026-02-06T23:59:59+00:00"
generated_at: "2026-05-16T04:02:30.212277+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# ENvue Medical amends CEO equity plan, appoints David Johnson as Chairman with 3.5% RSU grant

## Summary
- Amendment changes CEO Doron Besser's equity grants from annual to quarterly, with prorated gross-up on termination without cause.
- David Johnson appointed Chairman; receives $10k/month and RSUs representing 3.5% of fully diluted common stock.
- Chairman's RSUs vest over 2 years with anti-dilution protection; agreement auto-renews annually unless terminated.
- Besser's initial RSU grant remains 9% of fully diluted shares, subject to Israeli Tax Authority approval.
- Both agreements effective February 2, 2026.

## SEC filing metadata
- accession: 0001493152-26-005555
- form_type: 8-K
- ticker: FEED
- cik: 0001326706
- company_name: ENvue Medical, Inc.
- filed_at: 2026-02-06T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1326706/000149315226005555/0001493152-26-005555-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1326706/000149315226005555/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-005555
- JSON: https://secwatch.observer/filing/0001493152-26-005555.json
- Plain text: https://secwatch.observer/filing/0001493152-26-005555.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.